Cytomegalovirus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Cytomegalovirus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: ATA 230; CMV targeted T-cell therapy - Atara/MSKCC; CMV-CTL - Atara/MSKCC; CMV-peptide-specific T-cells - Atara/MSKCC; CMV-pp65 CTL - Atara/MSKCC; CMVpp65-specific T-cells - Atara/MSKCC; Cytomegalovirus virus specific cytotoxic T-lymphocytes - Atara/MSKCC

Latest Information Update: 08 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cytomegalovirus infections

Most Recent Events

  • 03 Jan 2017 Expanded-access programme by Atara Biotherapeutics for Cytomegalovirus infections treatment (Treatment-experienced) is temporarily unavailable in USA (NCT03010332)
  • 03 Dec 2016 Interim efficacy results from a phase II trial in Cytomegalovirus Targeted Cytotoxic T Lymphocytes presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 11 Oct 2016 European Medicines Agency (EMA) recommends orphan drug designation for cytomegalovirus-specific T-cell therapy in European Union for Cytomegalovirus infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top